Infusion pump tracking
This article was originally published in The Gray Sheet
Executive Summary
Disposable infusion pumps will not require tracking under an amendment currently being drafted to FDA's Feb. 19 final tracking guidance, FDA staffers say. The modification would nullify the risk-based differentiation of infusion pumps in the current guidance, which exempts pumps from tracking if they are "designated and labeled for use exclusively for fluids with low potential risks," such as enteral feeding and anti-infectives. Following the amendment, tracking would only be required for electromechanical infusion pumps
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.